The 60-second version of Sunil Healthcare Limited — what it does, how it earns, and who it competes with, before any of the numbers below.
| Metric | FY23 | FY24 | FY25 | FY26 | 3Y CAGR |
|---|---|---|---|---|---|
| Revenue | ₹110 Cr | ₹90 Cr | ₹83 Cr | ₹87 Cr | -7.5% |
| EBITDA | ₹20 Cr | ₹5 Cr | ₹11 Cr | ₹16 Cr | -8.2% |
| EBITDA Margin | 18.3% | 5.9% | 13.5% | 17.9% | — |
| PAT (Net Profit) | ₹7 Cr | -₹2 Cr | -₹1 Cr | ₹4 Cr | -15.7% |
| EPS | ₹6.52 | ₹-1.74 | ₹-1.38 | ₹3.91 | -15.7% |
| ROE | 11.9% | -2.6% | -2.1% | 5.8% | — |
| ROCE | 17.0% | 2.2% | 4.5% | 7.3% | — |
| Total Debt | ₹36 Cr | ₹65 Cr | ₹67 Cr | ₹54 Cr | +14.9% |
| Free Cash Flow | ₹3 Cr | -₹26 Cr | ₹2 Cr | ₹19 Cr | +78.4% |
| Company | P/E | ROE |
|---|---|---|
| SUN PHARMACEUTICAL IND L | 34.9x | 14.5% |
| DR. REDDY S LABORATORIES | 31.0x | 8.8% |
| CIPLA LTD | 31.8x | 9.8% |
| DIVI S LABORATORIES LTD | 83.0x | 17.5% |
The low price is the whole case here, and the business underneath scores poorly. Cheap-and-weak is what a value trap looks like from the outside — it needs a specific reason the numbers are about to improve, not just the observation that they are low. 3 high-severity red flags sit above this conclusion and should be read first.